|
1
|
A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans.
|
Clin Pharmacol Ther
|
2002
|
1.63
|
|
2
|
Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants.
|
J Clin Pharmacol
|
2010
|
0.80
|
|
3
|
Assessment of the cardiac safety and pharmacokinetics of a short course, twice daily dose of orally-administered mifepristone in healthy male subjects.
|
Cardiol J
|
2013
|
0.75
|
|
4
|
Assessment of the consistency of absorption of dihydroergotamine following oral inhalation: pooled results from four clinical studies.
|
J Aerosol Med Pulm Drug Deliv
|
2012
|
0.75
|